Stefanie Schulz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2535374/publications.pdf

Version: 2024-02-01

131 papers	8,808 citations	50566 48 h-index	48101 92 g-index
135 all docs	135 docs citations	135 times ranked	7639 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial. Journal of Atherosclerosis and Thrombosis, 2022, 29, 747-761.	0.9	4
2	Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y₁₂ Inhibitor Thereafter. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1001-1019.	0.9	2
3	Access route and clinical outcomes after ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing invasive treatment strategy. Cardiovascular Revascularization Medicine, 2022, , .	0.3	0
4	Preadmission antiplatelet therapy and treatment effect of ticagrelor versus prasugrel in patients with acute coronary syndromes - a subgroup analysis of the ISAR-REACT 5 trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	1.4	1
5	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention. JAMA Cardiology, 2021, 6, 1121.	3.0	11
6	Tenâ€Year Clinical Outcomes of Biodegradable Versus Durable Polymer Newâ€Generation Drugâ€Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e020165.	1.6	5
7	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e010565.	1.4	4
8	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to EstimatedÂGlomerular Filtration Rate. JACC: Cardiovascular Interventions, 2021, 14, 1857-1866.	1.1	9
9	Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1117-1124.	0.4	5
10	Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. Journal of the American Heart Association, 2021, 10, e021418.	1.6	1
11	Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.4	0
12	Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated?. Revista Espanola De Cardiologia (English Ed), 2020, 73, 225-231.	0.4	0
13	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thrombosis and Haemostasis, 2020, 120, 348-362.	1.8	13
14	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and DiabetesÂMellitus. JACC: Cardiovascular Interventions, 2020, 13, 2238-2247.	1.1	27
15	Ticagrelor or Prasugrel in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2020, 142, 2329-2337.	1.6	26
16	Sex differences in the outcome after percutaneous coronary intervention â€“ A propensity matching analysis. Cardiovascular Revascularization Medicine, 2019, 20, 101-107.	0.3	17
17	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2019, 381, 1524-1534.	13.9	543
18	Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions. Journal of the American College of Cardiology, 2018, 71, 1973-1982.	1.2	52

#	Article	IF	Citations
19	Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women. Circulation: Cardiovascular Interventions, 2018, 11, e006074.	1.4	12
20	Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2018, 92, 1239-1246.	0.7	5
21	Increased bleeding risk during percutaneous coronary interventions by arterial hypertension. Catheterization and Cardiovascular Interventions, 2016, 88, 184-190.	0.7	6
22	Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Thrombosis Research, 2016, 137, 72-78.	0.8	6
23	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. EuroIntervention, 2016, 11, 1372-137.	1.4	60
24	Motivations for and barriers to choosing an interventional cardiology career path: results from the EAPCI Women Committee worldwide survey. EuroIntervention, 2016, 12, 53-59.	1.4	48
25	Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. EuroIntervention, 2016, 11, e1275-e1282.	1.4	0
26	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.8	17
27	Assessing the Benefit of Vascular Closure Devices After Femoral Artery Punctureâ€"Reply. JAMA - Journal of the American Medical Association, 2015, 313, 855.	3.8	2
28	Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets, 2015, 26, 53-58.	1.1	22
29	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. European Heart Journal, 2015, 36, 1252-1263.	1.0	366
30	Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. European Heart Journal, 2015, 36, 3202-3210.	1.0	75
31	Reply. Journal of the American College of Cardiology, 2015, 65, 2154.	1.2	24
32	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2015, 8, 877-884.	1.1	85
33	The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. Thrombosis Research, 2015, 136, 87-93.	0.8	27
34	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2015, 65, 1619-1629.	1.2	401
35	Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2015, 39, 35-42.	1.0	21
36	Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. American Heart Journal, 2014, 168, 862-868.e1.	1.2	9

#	Article	IF	Citations
37	Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. Catheterization and Cardiovascular Interventions, 2014, 83, 182-189.	0.7	29
38	Correlates of poor outcome among patients with bleeding after coronary interventions. Coronary Artery Disease, 2014, 25, 456-462.	0.3	6
39	Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture. JAMA - Journal of the American Medical Association, 2014, 312, 1981.	3.8	162
40	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: Results from the ISAR-DESIRE 2 trial. Cardiovascular Revascularization Medicine, 2014, 15, 69-75.	0.3	12
41	Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. Clinical Research in Cardiology, 2014, 103, 49-56.	1.5	13
42	Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategyâ€"Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial. Journal of Cardiovascular Translational Research, 2014, 7, 91-100.	1.1	84
43	Impact of Coronary Anatomy and Stenting Technique on Long-Term Outcome AfterÂDrug-Eluting Stent Implantation for Unprotected Left Main Coronary ArteryÂDisease. JACC: Cardiovascular Interventions, 2014, 7, 29-36.	1.1	44
44	Rationale and design of The Intracoronary Stenting and Antithrombotic Regimenâ€"Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. American Heart Journal, 2014, 167, 459-465.e1.	1.2	19
45	Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With <scp>ST</scp>â€Segment Elevation Myocardial Infarction: Design and Rationale of the Bavarian Reperfusion Alternatives Evaluation (<scp>BRAVE</scp>) 4 Trial. Clinical Cardiology, 2014, 37, 270-276.	0.7	17
46	Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 64, 863-871.	1.2	88
47	Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. European Heart Journal, 2014, 35, 2285-2294.	1.0	93
48	A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 342-351.	1.8	41
49	Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Thrombosis and Haemostasis, 2014, 112, 1190-1197.	1.8	27
50	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Thrombosis and Haemostasis, 2014, 111, 1041-1049.	1.8	16
51	Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. EuroIntervention, 2014, 10, 83-89.	1.4	3
52	Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site â€“ CLOSURE device versus manual compression (ISAR-CLOSURE) trial. EuroIntervention, 2014, 10, 198-203.	1.4	8
53	Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2013, 62, 2075-2082.	1.2	69
54	Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet, The, 2013, 381, 461-467.	6.3	347

#	Article	IF	Citations
55	Sex-related effectiveness of bivalirudin versus abciximab and heparin in nonâ€“ST-segment elevation myocardial infarction. American Heart Journal, 2013, 165, 537-543.	1.2	13
56	Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-ElutingÂStents. JACC: Cardiovascular Interventions, 2013, 6, 1267-1274.	1.1	286
57	Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. American Heart Journal, 2013, 166, 534-540.	1.2	42
58	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology, 2013, 167, 575-584.	0.8	160
59	Comparative efficacy of 2 zotarolimus-eluting stent generations: Resolute versus endeavor stents in patients with coronary artery disease. American Heart Journal, 2013, 165, 80-86.	1.2	33
60	Prognostic Value of Access and Nonâ€“Access Sites Bleeding After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 354-361.	1.4	53
61	Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. European Heart Journal, 2013, 34, 872-874.	1.0	2
62	Collagen Plug Vascular Closure Devices and Reduced Risk of Bleeding with Bivalirudin Versus Heparin Plus Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Non <scp>ST</scp>â€<scp>S</scp>egment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2013, 26, 623-629.	0.5	4
63	Secondâ€versus firstâ€generation â€œLimusâ€eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISARâ€TESTâ€4 trial. Catheterization and Cardiovascular Interventions, 2013, 82, E769-76.	0.7	13
64	High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring. Platelets, 2013, 24, 500-502.	1.1	2
65	Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thrombosis and Haemostasis, 2013, 109, 517-254.	1.8	12
66	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology, 2013, 167, 575-584.	0.8	87
67	One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. EuroIntervention, 2013, 9, 430-436.	1.4	21
68	No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting. Circulation: Cardiovascular Interventions, 2012, 5, 82-88.	1.4	37
69	Response to Letter Regarding Article, â€œValidation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Interventionâ€. Circulation, 2012, 126, .	1.6	0
70	Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Nonâ€“ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment. Circulation: Cardiovascular Interventions, 2012, 5, 705-712.	1.4	29
71	Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Circulation, 2012, 125, 1424-1431.	1.6	207
72	The impact of smoking on the antiplatelet action of clopidogrel in nonâ€STâ€elevation myocardial infarction patients: results from the ISARâ€REACTÂ4 platelet substudy. Journal of Thrombosis and Haemostasis, 2012, 10, 2199-2202.	1.9	8

#	Article	IF	Citations
73	Prognostic Value of a High On-Clopidogrel Treatment Platelet Reactivity in Bivalirudin Versus Abciximab Treated Nonâ€“ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2012, 60, 369-377.	1.2	40
74	Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. Thrombosis and Haemostasis, 2012, 107, 769-774.	1.8	10
75	Prognostic Value of Uric Acid in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2012, 109, 1260-1265.	0.7	72
76	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. European Heart Journal, 2011, 32, 1605-1613.	1.0	174
77	Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 1325-1331.	1.2	131
78	Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation?âŽâŽEditorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.. JACC: Cardiovascular Interventions, 2011, 4, 1129-1132.	1.1	15
79	Abciximab and Heparin versus Bivalirudin for Nonâ€“ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2011, 365, 1980-1989.	13.9	285
80	Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. American Heart Journal, 2011, 161, 68-75.	1.2	90
81	Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. Clinica Chimica Acta, 2011, 412, 1350-1356.	0.5	16
82	Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. Thrombosis Research, 2011, 127, 119-121.	0.8	16
83	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet, The, 2011, 378, 1071-1078.	6.3	164
84	Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. European Journal of Clinical Investigation, 2011, 41, 1054-1062.	1.7	12
85	High-Sensitivity Troponin T Level and Angiographic Severity of Coronary Artery Disease. American Journal of Cardiology, 2011, 108, 639-643.	0.7	52
86	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. Clinical Research in Cardiology, 2011, 100, 579-585.	1.5	4
87	Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. Clinical Research in Cardiology, 2011, 100, 691-699.	1.5	7
88	Fiveâ€year clinical outcomes of sirolimusâ€eluting versus paclitaxelâ€eluting stents in highâ€risk patients. Catheterization and Cardiovascular Interventions, 2011, 77, 494-501.	0.7	17
89	Polymer-Free Sirolimus- and Probucol-Eluting Versus New Generation Zotarolimus-Eluting Stents in Coronary Artery Disease. Circulation, 2011, 124, 624-632.	1.6	126
90	'Selective' reel syndrome?. Europace, 2011, 13, 143-143.	0.7	2

#	Article	IF	Citations
91	ISAR - A Story of Trials With Impact on Practice -. Circulation Journal, 2010, 74, 1771-1778.	0.7	6
92	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thrombosis and Haemostasis, 2010, 104, 626-632.	1.8	28
93	Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. Heart and Vessels, 2010, 25, 27-34.	0.5	23
94	Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. Heart and Vessels, 2010, 25, 294-298.	0.5	6
95	Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. Clinical Research in Cardiology, 2010, 99, 13-19.	1.5	10
96	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clinical Research in Cardiology, 2010, 99, 345-357.	1.5	34
97	One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. Clinical Research in Cardiology, 2010, 99, 795-802.	1.5	22
98	Bleeding After Percutaneous Coronary Intervention With Bivalirudin or Unfractionated Heparin and One-Year Mortality. American Journal of Cardiology, 2010, 105, 163-167.	0.7	25
99	Peak Cardiac Troponin-T Level, Scintigraphic Myocardial Infarct Size and One-Year Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. American Journal of Cardiology, 2010, 106, 1212-1217.	0.7	53
100	Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Journal of Thrombosis and Haemostasis, 2010, 8, 250-256.	1.9	305
101	Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2010, 3, 408-413.	1.4	122
102	Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. European Heart Journal, 2010, 31, 582-587.	1.0	57
103	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. European Heart Journal, 2010, 31, 2482-2491.	1.0	82
104	Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. European Heart Journal, 2010, 31, 1205-1211.	1.0	75
105	A Double-Blind, Randomized Study on Prevention and Existence of a Rebound Phenomenon of Platelets After Cessation of Clopidogrel Treatment. Journal of the American College of Cardiology, 2010, 55, 558-565.	1.2	55
106	Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents. Journal of the American College of Cardiology, 2010, 55, 2710-2716.	1.2	192
107	2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents. Journal of the American College of Cardiology, 2010, 55, 2536-2543.	1.2	108
108	Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients. Journal of the American College of Cardiology, 2010, 56, 317-318.	1.2	196

#	Article	IF	Citations
109	Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. American Heart Journal, 2010, 160, 355-361.	1.2	20
110	Abciximab in Patients With Acute ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading. Circulation, 2009, 119, 1933-1940.	1.6	300
111	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. European Heart Journal, 2009, 30, 2714-2721.	1.0	224
112	Choice of Contrast Medium in Patients With Impaired Renal Function Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2009, 2, 430-437.	1.4	44
113	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. European Heart Journal, 2009, 30, 2441-2449.	1.0	207
114	Prognostic Value of Kidney Function in Patients With ST-Elevation and Nonâ€“ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. American Journal of Kidney Diseases, 2009, 54, 830-839.	2.1	25
115	Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. JACC: Cardiovascular Interventions, 2009, 2, 1142-1148.	1.1	20
116	Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. Clinica Chimica Acta, 2009, 409, 46-51.	0.5	8
117	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. American Heart Journal, 2009, 157, 620-624.e2.	1.2	91
118	Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 53, 1760-1768.	1.2	180
119	Patterns of Presentation and Outcomes of Patients with Acute Coronary Syndromes. Cardiology, 2009, 113, 198-206.	0.6	36
120	Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. Clinical Science, 2009, 116, 651-658.	1.8	22
121	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clinical Research in Cardiology, 2008, 97, 160-168.	1.5	12
122	Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. Journal of Internal Medicine, 2008, 264, 472-480.	2.7	82
123	Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2008, 52, 512-517.	1.2	69
124	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. European Heart Journal, 2008, 30, 290-296.	1.0	51
125	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. European Heart Journal, 2008, 29, 1975-1982.	1.0	182
126	Glycoprotein IIb/IIIa Receptor Inhibition with Abciximab during Percutaneous Coronary Interventions Increases the Risk of Bleeding in Patients with Impaired Renal Function. Cardiology, 2008, 111, 247-253.	0.6	10

#	Article	IF	Citations
127	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. European Heart Journal, 2008, 30, 923-931.	1.0	123
128	Arylsulfatase G, a Novel Lysosomal Sulfatase. Journal of Biological Chemistry, 2008, 283, 11388-11395.	1.6	41
129	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. New England Journal of Medicine, 2008, 359, 688-696.	13.9	323
130	Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Thrombosis and Haemostasis, 2007, 98, 852-857.	1.8	67
131	Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thrombosis and Haemostasis, 2007, 98, 852-7.	1.8	33